GlassScriptPhysician profile
Dena K Lowe
NPI 1356035752
$4,177.01
in general payments reported to CMS, 2019-2025
34 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $376 · 2024: $1,930 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.70 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $582.73 | 2023-2025 | Rybrevant, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $392.98 | 2023-2025 | |
| Eisai INC. | $289.37 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $240.27 | 2023-2025 | Keytruda, Lynparza |
| Pfizer INC. | $195.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.13 | 2024-2025 | Ninlaro, Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $141.62 | 2024-2025 | Somatuline Depot, Onivyde |
| Genzyme Corporation | $139.19 | 2024-2025 | |
| Exelixis INC. | $134.82 | 2023-2025 | Cabometyx |
| Stemline Therapeutics INC. | $130.54 | 2024-2025 | Orserdu |
| Glaxosmithkline, LLC. | $118.31 | 2024-2025 | Ojjaara, Blenrep |
| Daiichi Sankyo INC. | $109.30 | 2024-2025 | Enhertu, Datroway |
| Sobi, INC | $83.47 | 2024-2025 | |
| Genmab U.S., INC. | $71.85 | 2023-2024 | Tivdak |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $71.32 | 2023-2025 | Xpovio |
| Taiho Oncology, INC. | $68.51 | 2024 | |
| Beigene USA, INC. | $65.12 | 2024-2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $62.95 | 2023-2025 | |
| Celgene Corporation | $62.31 | 2025 | Reblozyl |
| Astellas Pharma US INC | $48.63 | 2025 | Xtandi, Vyloy |
| Emd Serono, INC. | $47.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.91 | 2025 | |
| Servier Pharmaceuticals LLC | $40.64 | 2023-2024 | |
| Array Biopharma INC | $37.74 | 2025 | Lorbrena, Braftovi |
| Pharmacosmos Therapeutics INC. | $36.49 | 2023-2024 | Monoferric |
| Genentech USA, INC. | $28.84 | 2025 | Phesgo, Itovebi |
| Incyte Corporation | $26.10 | 2025 | Zynyz |
| Abbvie INC. | $23.11 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.11 | 2023 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $17.96 | 2025 | Jaypirca, Verzenio |
| Azurity Pharmaceuticals, INC. | $17.61 | 2024 | Vivimusta |
| Beone Medicines USA, INC. | $13.64 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $13.64 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.